The MAYO PROTEIN CORE (MPC) was integrated as a shared resource of the Mayo Clinic Cancer Center in 1992, and since that time the core has experienced a rapid growth and continued expansion of its services by Cancer Center members. The facility has supported a broad diversity of projects related to cancer research, and has thus served in an indispensable capacity to members of the Mayo Clinic Cancer Center. The user base of this resource has steadily increased from 21 center members in 1991, to 47 members in 1997. The seven full-time staff of the resource provide a broad range of services related to protein analysis, synthesis and isolation to members in both basic and clinical sciences. The current services provided to Cancer Center members are: (1) N-terminal protein sequencing; (2) C-terminal protein sequencing by an alkylated-thiohydantoin chemistry; (3) Protein digestion and peptide separation by capillary liquid chromatography (cLC); (4) Quantitative and qualitative amino and analysis; (5) Solid phase peptide synthesis by Fmoc methods; (6) Production of peptide/protein specific immunogens on KLH/BSA carriers; (7) Protein/peptide purification by reverse phase HPLC and FPLC, and (8) Computer analysis of protein sequences for synthetic peptide design. The resource will also be offering the following new services to Cancer Center members comprising; (9) Two dimensional polyacrylamide gel electrophoresis (2-D PAGE); (10) Chemical synthesis of large polypeptides and small synthetic proteins; (11) Peptide nucleic acid (PNA) synthesis, and (12) Computational chemistry and molecular modeling of proteins and polypeptides.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-27
Application #
6444586
Study Section
Project Start
2001-04-05
Project End
2002-02-28
Budget Start
Budget End
Support Year
27
Fiscal Year
2001
Total Cost
$228,401
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8

Showing the most recent 10 out of 1129 publications